Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients.

Reinhold, Ilana; Blümel, Sena; Schreiner, Jens; Boyman, Onur; Bögeholz, Jan; Cheetham, Marcus; Rogler, Gerhard; Biedermann, Luc; Scharl, Michael

Reinhold, Ilana; Blümel, Sena; Schreiner, Jens; Boyman, Onur; Bögeholz, Jan; Cheetham, Marcus; Rogler, Gerhard; Biedermann, Luc; Scharl, Michael.

Afiliação

Reinhold I; Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Blümel S; Department of Internal Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Schreiner J; Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Boyman O; Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
Bögeholz J; Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
Cheetham M; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Rogler G; Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Biedermann L; Department of Internal Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Scharl M; Department of Internal Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Inflamm Intest Dis ; 6(1): 38-47, 2021 Feb.

Article em En | MEDLINE | ID: mdl-33850838

Palavras-chave

Adalimumab; Anti-drug antibodies; Anti-tumor necrosis factor; Crohn's disease; Inflammatory bowel disease; Infliximab; Trough level measurement; Ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Inflamm Intest Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google